Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis
Sponsor: King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Terminated
Lack of funding
Other terminated trials from King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
More terminations from King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
A EARLY_PHASE1 clinical study on Metabolic Syndrome, this trial is terminated or withdrawn. The trial is conducted by King Pharmaceuticals is now a wholly owned subsidiary of Pfizer and has accumulated 11 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Terminated EARLY_PHASE1
-
Dec 2021 — Dec 2022 [monthly]
Terminated EARLY_PHASE1
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated EARLY_PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Terminated EARLY_PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Terminated EARLY_PHASE1
-
Jun 2018 — Sep 2019 [monthly]
Terminated EARLY_PHASE1
-
May 2017 — Jun 2018 [monthly]
Terminated EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
Jan 2017 — May 2017 [monthly]
Terminated NA
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
- University of Maryland, Baltimore
For direct contact, visit the study record on ClinicalTrials.gov .